NovoSeven: payments to doctors
Payments that named NovoSeven as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $583K
- Providers
- 463
- Transactions
- 942
- Average per transaction
- $619
The per-transaction average — $619 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 463 providers the average total is $1,260, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novo Nordisk | $442,808 | 75.9% |
| Novo Nordisk Health Care AG | $90,035 | 15.4% |
| Novo Nordisk AS | $50,456 | 8.7% |